GO:0045541 negative regulation of cholesterol biosynthetic process: Pathway Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045541 describes any biological process that reduces the rate or extent of cholesterol biosynthesis, the multi-step conversion of acetyl-CoA to cholesterol.
• Cholesterol biosynthesis is energetically expensive and is tightly coupled to nutrient status, including glutamine availability, which licenses pathway activity.
• Key control nodes include SREBP/SCAP trafficking, HMGCR stability, and post-translational modification such as SCAP S-acylation by ZDHHC3.
• Loss of negative regulation causes cholesterol accumulation that can drive ferroptosis resistance, tumorigenicity, and immune escape.
• Mitochondrial cholesterol handling intersects with redox biology, steroidogenesis, and disease, linking GO:0045541 to organelle-level regulation.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to test causality of candidate regulators in this pathway.
Description
GO:0045541, negative regulation of cholesterol biosynthetic process, is a Gene Ontology biological_process term that captures any mechanism that decreases the rate or extent of cholesterol biosynthesis. Cholesterol is an essential membrane lipid and precursor for steroid hormones, bile acids, and vitamin D, but its accumulation is cytotoxic and is associated with cardiovascular, metabolic, and neoplastic disease. Because the pathway consumes large amounts of acetyl-CoA, ATP, and reducing equivalents, cells must continuously adjust its output to match nutrient availability and demand. Understanding negative regulation is therefore central to physiology and to therapeutic strategies that target lipid metabolism. At the molecular level, negative regulation of cholesterol biosynthesis is not a single reaction but a network of feedback and feed-forward controls. These include sterol-sensing by SCAP and INSIG proteins, regulated degradation of HMG-CoA reductase, and post-translational modifications that alter pathway flux. Nutrient-sensing pathways, such as glutamine sensing, can license or restrict cholesterol synthesis, showing that negative regulation is integrated with general metabolic state. Mitochondrial cholesterol trafficking also influences the pathway and its downstream products, adding another layer of control. For researchers, GO:0045541 provides a standardized annotation for experiments that perturb cholesterol synthesis. It is used to interpret transcriptomic, proteomic, and lipidomic datasets and to connect candidate genes to disease phenotypes such as tumor immune escape and ferroptosis resistance. This article summarizes the definition, core mechanisms, key genes, disease links, and CRISPR-based methods used to study negative regulation of cholesterol biosynthetic process.
negative regulation of cholesterol biosynthetic process At A Glance
| GO ID | GO:0045541 |
|---|---|
| GO term | negative regulation of cholesterol biosynthetic process |
| Ontology | biological_process |
| Synonym | none listed in QuickGO |
| Major function | Reduces the rate or extent of cholesterol biosynthesis |
| Biological context | Lipid homeostasis, nutrient sensing, membrane biogenesis |
| Representative regulators | SCAP, INSIG1/2, HMGCR, SREBF2, ZDHHC3 |
| Disease relevance | Cancer, metabolic disease, ferroptosis resistance, immune escape |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, lipidomics, RNA-seq |
What Is GO:0045541?
In our own words, GO:0045541 refers to any biological process that reduces the frequency, rate, or extent of cholesterol biosynthesis. It includes direct inhibition of biosynthetic enzymes, transcriptional repression of pathway genes, accelerated degradation of rate-limiting enzymes, and signaling events that lower flux through the mevalonate pathway. The term is a negative regulatory process, meaning it is defined by its effect on cholesterol biosynthetic process rather than by a single molecular mechanism.
Why Is negative regulation of cholesterol biosynthetic process Important in Cell Biology?
Negative regulation of cholesterol biosynthesis is important because uncontrolled cholesterol synthesis promotes membrane rigidity, lipotoxicity, and tumor progression, while excessive suppression impairs proliferation and hormone production. The pathway is a major consumer of acetyl-CoA and NADPH, so its negative regulation is tightly linked to cellular energy and redox balance. Clinically, dysregulated cholesterol homeostasis can confer ferroptosis resistance and increase tumorigenicity and metastasis, making this GO term directly relevant to cancer biology and therapeutic resistance. In hepatocellular carcinoma, ZDHHC3-mediated SCAP S-acylation promotes cholesterol biosynthesis and tumor immune escape, illustrating how loss of negative regulation can drive immune evasion. Mitochondrial cholesterol metabolism further connects this process to steroidogenesis, redox biology, and organelle dysfunction. Consequently, GO:0045541 is a key annotation for studies of metabolic disease, cancer, immunometabolism, and drug discovery.
• Maintains membrane lipid homeostasis by preventing excessive cholesterol accumulation.
• Protects cells from lipotoxicity and oxidative stress linked to mitochondrial cholesterol.
• Supports nutrient sensing by coupling cholesterol synthesis to glutamine availability.
• Limits tumorigenicity and metastasis associated with dysregulated cholesterol homeostasis.
• Modulates anti-tumor immunity, as cholesterol biosynthesis can promote immune escape.
• Provides a mechanistic explanation for ferroptosis resistance in cancer cells.
• Serves as a target for statins and other lipid-lowering strategies.
• Helps interpret transcriptomic and lipidomic data in metabolic research.
• Connects intestinal lipid absorption to T cell cholesterol transport and immune responses.
• Guides CRISPR-based validation of candidate regulators in disease models.
What Happens During negative regulation of cholesterol biosynthetic process?
Sterol sensing and SREBP/SCAP control
In simple terms: Cells sense when cholesterol is high and switch off the machinery that makes more.
When sterol levels rise, the sterol-sensing protein SCAP changes conformation and binds INSIG proteins, retaining the SREBP transcription factor complex in the endoplasmic reticulum and preventing its activation. This reduces transcription of cholesterol biosynthetic genes, a classic example of negative regulation of cholesterol biosynthetic process. Post-translational modification of SCAP, such as S-acylation by ZDHHC3, can alter this control and promote cholesterol biosynthesis, indicating that negative regulation is dynamically modulated.
Regulated degradation of HMG-CoA reductase
In simple terms: The rate-limiting enzyme of cholesterol synthesis is destroyed when it is not needed.
HMG-CoA reductase (HMGCR) is the rate-limiting enzyme of the mevalonate pathway, and its stability is controlled by sterol and non-sterol signals. Negative regulation of cholesterol biosynthetic process includes accelerated degradation of HMGCR, which rapidly lowers pathway flux. This degradation is part of a feedback system that prevents overproduction of cholesterol and its intermediates.
Nutrient and metabolic licensing
In simple terms: Making cholesterol requires building blocks, so cells check nutrient levels before proceeding.
Glutamine sensing licenses cholesterol synthesis, meaning that the pathway is permitted only when sufficient glutamine and related metabolites are available. This links negative regulation of cholesterol biosynthetic process to general nutrient status and to the integration of carbon and nitrogen metabolism. Mitochondrial cholesterol metabolism also intersects with redox biology, providing additional metabolic inputs that can restrain or support the pathway.
Transcriptional and post-transcriptional feedback
In simple terms: Cells reduce the messages and proteins needed for cholesterol production when levels are adequate.
Negative regulation of cholesterol biosynthetic process includes reduced transcription of SREBP target genes and post-transcriptional mechanisms that lower enzyme abundance. tRNA modifications such as N1-methyladenosine can regulate cholesterol metabolism, showing that RNA-level control contributes to pathway output. These layers ensure that cholesterol synthesis is suppressed when demand is low.
Organelle-level and systemic control
In simple terms: Cholesterol regulation also happens across organelles and even between organs.
Mitochondrial cholesterol trafficking influences steroidogenesis and redox balance, and its dysregulation is associated with disease. In the intestine, T cell cholesterol transport links dietary lipid absorption to immune responses, illustrating systemic control of cholesterol handling. These organelle and systemic inputs contribute to the negative regulation of cholesterol biosynthetic process by adjusting pathway activity to whole-body needs.
Key Genes Involved in GO:0045541 negative regulation of cholesterol biosynthetic process
The following genes and proteins are experimentally implicated in negative regulation of cholesterol biosynthetic process or in the broader cholesterol synthesis network.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HMGCR | Rate-limiting enzyme of cholesterol biosynthesis | Target of statins; regulated degradation controls pathway flux |
| SCAP | Sterol sensor that controls SREBP activation | S-acylation by ZDHHC3 promotes cholesterol biosynthesis and immune escape |
| INSIG1 | Retains SREBP complex in ER when sterols are high | Negative regulator of SREBP processing |
| INSIG2 | Paralog of INSIG1 in sterol sensing | Modulates SREBP pathway and cholesterol synthesis |
| SREBF2 | Transcription factor for cholesterol biosynthetic genes | Central node of feedback regulation |
| ZDHHC3 | Palmitoyl acyltransferase that S-acylates SCAP | Promotes cholesterol biosynthesis and tumor immune escape |
| GLS | Glutaminase that supports glutamine sensing | Glutamine sensing licenses cholesterol synthesis |
| SLC25A1 | Mitochondrial citrate carrier | Links mitochondrial metabolism to cholesterol synthesis |
| STAR | Cholesterol transport into mitochondria | Mitochondrial cholesterol metabolism and steroidogenesis |
| TSPO | Mitochondrial cholesterol import | Redox biology and disease links |
| CYP11A1 | Cholesterol side-chain cleavage enzyme | Mitochondrial cholesterol utilization |
| ABCA1 | Cholesterol efflux transporter | Systemic cholesterol transport and immune function |
| ABCG1 | Cholesterol efflux transporter | Cellular cholesterol homeostasis |
| APOE | Lipoprotein-mediated cholesterol transport | Systemic lipid transport |
| LDLR | Uptake of LDL cholesterol | Feedback control of cholesterol synthesis |
| NR1H2 | LXR beta nuclear receptor | Transcriptional control of cholesterol metabolism |
| NR1H3 | LXR alpha nuclear receptor | Transcriptional control of cholesterol metabolism |
How Is negative regulation of cholesterol biosynthetic process Regulated?
Negative regulation of cholesterol biosynthetic process is controlled by sterol feedback through SCAP-INSIG-SREBP signaling, by regulated degradation of HMGCR, and by nutrient-sensing inputs such as glutamine availability. Post-translational modification of SCAP by ZDHHC3 can override negative regulation and promote cholesterol biosynthesis, as shown in hepatocellular carcinoma. Mitochondrial cholesterol trafficking and redox state provide additional organelle-level control. Systemic signals, including intestinal lipid absorption and T cell cholesterol transport, also influence cholesterol handling and can indirectly affect pathway activity.
negative regulation of cholesterol biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SCAP | Hepatocellular carcinoma immune escape | ZDHHC3 knockout or SCAP point-mutation cells |
| HMGCR | Cholesterol homeostasis and ferroptosis resistance | HMGCR knockout or overexpression in cancer lines |
| GLS | Metabolic licensing of cholesterol synthesis | Glutamine-sensing knockout models |
| STAR | Mitochondrial cholesterol metabolism and redox disease | STAR knockout or tagged knock-in |
| ABCA1 | Intestinal immune responses and lipid absorption | T cell-specific knockout models |
Cancer and ferroptosis resistance
Dysregulated cholesterol homeostasis results in resistance to ferroptosis, increasing tumorigenicity and metastasis in cancer. Loss of negative regulation of cholesterol biosynthetic process can therefore promote tumor progression by altering lipid peroxidation and cell death sensitivity. In hepatocellular carcinoma, ZDHHC3-mediated SCAP S-acylation promotes cholesterol biosynthesis and tumor immune escape, linking pathway activation to immune evasion.
Metabolic and mitochondrial disease
Mitochondrial cholesterol metabolism impacts redox biology and disease, and its dysregulation is associated with organelle dysfunction. Because negative regulation of cholesterol biosynthetic process controls the supply of cholesterol to mitochondria, defects in this control can affect steroidogenesis and oxidative stress. Nutrient-sensing defects that alter glutamine-dependent licensing of cholesterol synthesis may also contribute to metabolic pathology.
Immune and intestinal biology
T cell cholesterol transport links intestinal immune responses to dietary lipid absorption, showing that cholesterol handling affects immunity. When negative regulation of cholesterol biosynthetic process is perturbed, changes in cholesterol availability can alter T cell function and intestinal immune homeostasis. This has implications for inflammatory and metabolic diseases.
From negative regulation of cholesterol biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for negative regulation of cholesterol biosynthesis? | CRISPR knockout in HepG2 or HeLa cells |
| Does a specific phosphorylation or acylation site control pathway activity? | Point-mutation knock-in at the modification site |
| Does a disease-associated variant alter cholesterol synthesis? | Knock-in of the variant allele |
| Where and when is the regulator expressed? | Tagged knock-in with fluorescent or epitope tag |
| Does overexpression of a regulator suppress cholesterol synthesis? | Doxycycline-inducible overexpression |
| Which genes modify the phenotype in a genome-wide manner? | CRISPR library screening |
How to Study the negative regulation of cholesterol biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics | Cholesterol and intermediate levels | Confirm pathway output after CRISPR perturbation |
| RNA-seq | Expression of cholesterol biosynthetic genes | Assess transcriptional negative regulation |
| Proteomics | HMGCR and SCAP protein abundance/modifications | Detect regulated degradation and S-acylation |
| Metabolic flux analysis | Rate of cholesterol synthesis | Test nutrient-dependent licensing |
| CRISPR knockout | Requirement of a gene for pathway regulation | Causal gene validation |
| CRISPR point mutation | Role of a specific residue or modification | Mechanistic dissection |
| CRISPR knock-in | Variant or tag effects in endogenous locus | Disease variant modeling |
| CRISPR overexpression | Sufficiency of a regulator to suppress synthesis | Gain-of-function studies |
Lipidomics and cholesterol quantification
Lipidomics and direct cholesterol assays measure the output of the pathway and can detect changes caused by negative regulators. These methods are used to confirm that a genetic perturbation alters cholesterol biosynthesis.
Transcriptomics and RNA-seq
RNA-seq measures expression of SREBP target genes and other pathway components, providing a readout of transcriptional negative regulation. It is often combined with CRISPR perturbation to identify causal regulators.
Proteomics and post-translational modification analysis
Proteomics can quantify HMGCR stability and detect modifications such as SCAP S-acylation that modulate negative regulation. These approaches link molecular changes to pathway flux.
Metabolic flux and nutrient-sensing assays
Flux assays using labeled precursors measure cholesterol synthesis rates and reveal how nutrient sensing, such as glutamine availability, licenses the pathway. Mitochondrial cholesterol trafficking can be assessed with organelle-targeted probes.
How CRISPR Can Be Used to Study GO:0045541 negative regulation of cholesterol biosynthetic process
Knockout
CRISPR knockout of candidate regulators such as ZDHHC3 or HMGCR can test whether they are required for negative regulation of cholesterol biosynthetic process. Knockout cells are then analyzed by lipidomics and RNA-seq to quantify pathway output.
Point Mutation
Point-mutation knock-in can disrupt specific modification sites, such as SCAP S-acylation sites, to determine whether a single residue controls pathway activity. This approach provides mechanistic evidence beyond simple loss-of-function.
Knock-in
Knock-in of disease-associated variants or epitope tags allows study of endogenous regulation of cholesterol synthesis. Tagged knock-in enables imaging and proteomic analysis of the regulator in its native context.
Overexpression
Overexpression of a negative regulator can test sufficiency to suppress cholesterol biosynthesis and downstream phenotypes such as immune escape. Inducible systems allow dose- and time-controlled experiments.
How EDITGENE Supports negative regulation of cholesterol biosynthetic process Research
Researchers studying negative regulation of cholesterol biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in pathway control or is merely correlated with changes in cholesterol levels. CRISPR-based models provide the necessary causal evidence by introducing precise genetic perturbations in relevant cell types.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of cholesterol biosynthetic process research.
Frequently Asked Questions About negative regulation of cholesterol biosynthetic process
What is GO:0045541?
GO:0045541 is the Gene Ontology term for negative regulation of cholesterol biosynthetic process, describing any process that reduces the rate or extent of cholesterol synthesis.
What does negative regulation of cholesterol biosynthetic process mean?
It means cellular mechanisms that lower cholesterol production, such as sterol feedback, enzyme degradation, and nutrient sensing.
What genes are involved in negative regulation of cholesterol biosynthetic process?
Key genes include HMGCR, SCAP, INSIG1, INSIG2, SREBF2, and ZDHHC3, among others.
How is cholesterol biosynthesis negatively regulated?
It is regulated by sterol sensing through SCAP-INSIG-SREBP, regulated degradation of HMGCR, and nutrient-dependent licensing such as glutamine sensing.
Why is negative regulation of cholesterol biosynthesis important in cancer?
Loss of negative regulation can cause cholesterol accumulation, ferroptosis resistance, tumorigenicity, and immune escape.
What is the role of SCAP in cholesterol regulation?
SCAP senses sterols and controls SREBP activation; its S-acylation by ZDHHC3 can promote cholesterol biosynthesis.
How do researchers study GO:0045541?
They use CRISPR knockout, point mutation, knock-in, overexpression, lipidomics, RNA-seq, and proteomics.
What diseases are linked to cholesterol biosynthesis dysregulation?
Cancer, metabolic disease, and mitochondrial dysfunction are linked to altered cholesterol homeostasis.
Can CRISPR be used to study cholesterol biosynthesis?
Yes, CRISPR knockout and point-mutation models are widely used to test causal roles of genes in cholesterol synthesis.
What is the connection between glutamine and cholesterol synthesis?
Glutamine sensing licenses cholesterol synthesis, linking nutrient status to pathway activity.
Conclusion
GO:0045541, negative regulation of cholesterol biosynthetic process, is a central node in lipid homeostasis that integrates sterol feedback, nutrient sensing, and organelle-level control. Its dysregulation is linked to cancer, ferroptosis resistance, immune escape, and metabolic disease, making it a high-value target for mechanistic and translational research. CRISPR-based knockout, point-mutation, knock-in, and overexpression models, combined with lipidomics and transcriptomics, provide the causal evidence needed to move from correlation to mechanism.
References
- 1. Goicoechea L et al.. 2023. Mitochondrial cholesterol: Metabolism and impact on redox biology and disease.. Redox Biol 61:102643 PMID: 36857930
- 2. Gao Y et al.. 2025. T cell cholesterol transport links intestinal immune responses to dietary lipid absorption.. Science 390(6769):eadt4169 PMID: 41066556
- 3. Garcia BM et al.. 2024. Glutamine sensing licenses cholesterol synthesis.. EMBO J 43(23):5837-5856 PMID: 39433901
- 4. Liu W et al.. 2021. Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer.. Nat Commun 12(1):5103 PMID: 34429409
- 5. Wu M et al.. 2024. ZDHHC3-mediated SCAP S-acylation promotes cholesterol biosynthesis and tumor immune escape in hepatocellular carcinoma.. Cell Rep 43(11):114962 PMID: 39522165
- 6. Norum KR et al.. 1983. Transport of cholesterol.. Physiol Rev 63(4):1343-419 PMID: 6361811
- 7. Wang Y et al.. 2021. N(1)-methyladenosine methylation in tRNA drives liver tumourigenesis by regulating cholesterol metabolism.. Nat Commun 12(1):6314 PMID: 34728628
